Growth failure and intestinal inflammation.
Ballinger
A B
AB
Digestive Diseases Research Centre, St Bartholomew's and The Royal London School of Medicine and Dentistry, London, UK. A.B.Ballinger@mds.qmw.ac.uk
Camacho-Hübner
C
C
Croft
N M
NM
D000293:Adolescent; D000818:Animals; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D002648:Child; D003424:Crohn Disease / Q000150:complications / Q000378:metabolism / Q000628:therapy; D002149:Energy Intake; D004750:Enteral Nutrition; D006130:Growth Disorders / Q000209:etiology* / Q000378:metabolism / Q000628:therapy; D006133:Growth Substances / Q000378:metabolism; D006801:Humans; D015212:Inflammatory Bowel Diseases / Q000150:complications* / Q000378:metabolism / Q000628:therapy; D007334:Insulin-Like Growth Factor I / Q000378:metabolism; D015850:Interleukin-6 / Q000378:metabolism; D051379:Mice; D008822:Mice, Transgenic; D051381:Rats; D012008:Recurrence; D012074:Remission Induction; D013256:Steroids; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism
D000893:Anti-Inflammatory Agents; D006133:Growth Substances; D015850:Interleukin-6; D013256:Steroids; D014409:Tumor Necrosis Factor-alpha; D007334:Insulin-Like Growth Factor I